Pluri CEO Issues Shareholder Update
Pluristem Therapeutics, Inc. HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc....
- Supported exchanges /
- TA /
- PSTI.TA
Pluristem (PSTI TA) stock market data APIs
ILA1825
-36(-1.9%)
as of November 21, 2024
Price chart is built with Anychart
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Pluristem Financial Data Overview
| 1861 | |
| 1825 | |
| - | |
| 1861 | |
| 1808 | |
| 192.9-2960 | |
| 117 M | |
| 32 348 K | |
| 234 K | |
| -0.08 | |
| 0 | |
| 1.9127 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'PSTI',
Type:
'Common Stock',
Name:
'Pluristem',
Exchange:
'TA',
CurrencyCode:
'ILA',
CurrencyName:
'Israeli Agora',
CurrencySymbol:
'ILA',
CountryName:
'Israel',
CountryISO:
'Il',
OpenFigi:
NULL,
ISIN:
NULL,
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'June',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Biotechnology & Medical Research',
CUSIP:
NULL,
}
Pluristem Fundamental Data is available in our Financial Data APIs
- Net Revenue 234 K
- EBITDA -46 047 000
- Earnings Per Share -1.462
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Pluristem Earnings via APIs
- Latest Release 2018-06-30
- EPS/Forecast NaN
Get Pluristem End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Pluristem latest news via APIs
Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries
Pluristem Therapeutics, Inc. Pluri Inc. logo WHERE TECHNOLOGY COMES TO LIFE As ofJuly 26, 2022, Pluri’s stock will trade under the symbol PLUR The new name reflects the Company’s strategy to lev...
- CELL-BASED
- COMPANY
- PLURI
- PLURI INC
- TECHNOLOGY
- THE COMPANY
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
